Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 142

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 142
---
 paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases$688 $405 Operating cash flows from short-term leases127 177 Operating cash flows from variable lease costs36 39 Right-of-use assets obtained in exchange for lease liabilities:Operating leases$1,115 $419 Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate):September 30,2025December 31,2024Finance LeasesProperty and equipment, at cost$1,031 $1,031 Less: accumulated depreciation and amortization(1,026)(1,023)Property and equipment, net$5 $8 Operating LeasesOperating lease right-of-use assets$1,337 $657 Current portion of operating lease liabilities$441 $420 Operating lease liabilities, less current portion966 372 Total operating lease liabilities$1,407 $792 Weighted Average Remaining Lease TermOperating leases (in years)33Weighted Average Discount RateOperating leases12.9%9.9%Maturities of lease liabilities were as follows (in thousands):Year Ended December 31,OperatingLeases2025 (excluding the nine months ended September 30, 2025)$172 2026552 2027542 2028393 202939 Total lease payments1,698 Less: future interest expense(291)Lease liabilities$1,407 

26

L.    Goodwill & Intangible AssetsThe Company's goodwill balance was $4.7 million as of September 30, 2025, and December 31, 2024. As of September 30, 2025, and December 31, 2024, non-amortizable intangible assets include $2.0 million related to in-process research and development associated with the Merger.The definite-lived intangible assets that are subject to amortization have been reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. In the second quarter of 2025, the Company assessed the results of its refined commercial efforts related to OLPRUVA. This was determined to be a triggering event that could result in a decrease in future expected cash flows, and thus indicated the carrying amount of the OLPRUVA asset group may not be fully recoverable. The Company performed an undiscounted cash flow analysis over the OLPRU